WEBINAR | Psychedelics 3.0: Challenges and Opportunities in a Rapidly Evolving Field
This webinar explores the unique clinical, operational and regulatory challenges facing psychedelic treatments.
There is a significant unmet need for medicines to treat neuropsychiatric and neurological conditions in underserved patient populations. Recently, there has been renewed interest in psychedelic, hallucinogenic and dissociative compounds to meet those needs. In clinical trials, a wide array of these compounds are showing efficacy across a variety of indications.
This webinar will cover how psychedelics have progressed from their origins as a spiritual aid to their acceptance as a treatment for neuropsychiatric conditions to the development of next-generation compounds (neuroplastogens) that seek to preserve neuroplasticity-promoting benefits without the hallucinogenic or psychomimetic effects.
Join leading experts as they each provide their own unique perspectives during a round-table open discussion about the current and future state of psychedelic drug development and how to actively navigate the rapidly evolving field of clinical trials for these revolutionary treatments.
Related Content
Looking for exclusive insight?
